Opendata, web and dolomites

SMARTRIOX SIGNED

Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SMARTRIOX project word cloud

Explore the words cloud of the SMARTRIOX project. It provides you a very rough idea of what is the project "SMARTRIOX" about.

threshold    bc    cardiac    itself    mg2    200    billion    ease    although    orphan    ttriple    achieves    tnbc    diagnosis    extremely    roi    mainstay    primary    primarily    helpful    25    course    national    molecular    responding    services    chemotherapy    triox    render    setting    poor    free    inside    limit    turn    company    prognosis    txn770    effectiveness    levels    dnazyme    negative    burden    10    estrogen    immune    metastatic    shortened    neoadjuvant    prevents    atp    dose    exclusively    herceptin    receptors    cancer    15    accounts    recognizes    nonetheless    world    substantial    oncologists    programmed    endocrine    epithelial    lacks    nano    disease    releases    2021    tumour    digestive    17    patients    causes    anthracycline    progesterone    concentrations    547m    lower    economic    therapies    breast    maximal    adjuvant    bcs    innovative    resistant    diagnosed    health    anticancer    positioning    doxorubicin    settings    toxicities    interval    trioxnano    suffering    treatment    cells    profit    times    bionanoparticle    machine    market    aggressive    shows    women    potent    yearly    invested    grow    date    cap   

Project "SMARTRIOX" data sheet

The following table provides information about the project.

Coordinator
TRIOX NANO LTD 

Organization address
address: ROKACH SHIMON 4
city: JERUSALEM
postcode: 9518705
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.smartriox.com
 Total cost 2˙847˙667 €
 EC max contribution 1˙993˙367 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRIOX NANO LTD IL (JERUSALEM) coordinator 1˙993˙367.00

Map

 Project objective

Although there are tTriple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2 and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.

 Deliverables

List of deliverables.
Project Web page Websites, patent fillings, videos etc. 2020-01-14 14:23:12

Take a look to the deliverables list in detail:  detailed list of SMARTRIOX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTRIOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMARTRIOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More